HCG: A Real Hormone Attached to a Refuted Diet Claim

No — in controlled trials, human chorionic gonadotropin produces no weight loss beyond what the accompanying diet produces on its own. That conclusion is unusually secure: a criteria-based meta-analysis of the published trials found no scientific evidence that hCG affects weight loss, fat distribution, hunger or wellbeing when given alongside a restricted diet 5. What makes the compound worth an article is everything else. hCG is a well-characterised hormone with a defined receptor and approved clinical uses in fertility medicine and male endocrinology. Those uses rest on evidence the diet claim never had — and the diet claim survived for decades partly because they exist.

What the molecule actually is

Human chorionic gonadotropin is produced by the syncytiotrophoblast of the placenta, and it is the hormone a pregnancy test detects. Structurally it is a heterodimer: two different chains, non-covalently associated, inactive apart and active together. The alpha chain runs to 92 amino acids and the beta chain to 145 — around 237 residues, before any carbohydrate is counted. The carbohydrate is substantial: the mature molecule carries both N-linked and O-linked glycans, and sugar accounts for roughly a third of its molecular weight 1.

The alpha subunit is not unique to hCG. The identical chain, from the same gene, appears in luteinising hormone, follicle-stimulating hormone and thyroid-stimulating hormone; all four glycoprotein hormones share it. What separates them is the beta subunit, which differs in each and determines which receptor the assembled dimer recognises. The beta chain of hCG closely resembles that of luteinising hormone but carries an additional C-terminal extension bearing O-linked sugars — a large part of why hCG persists in circulation far longer than LH does 1.

Why this is a protein, not a peptide

The line between a peptide and a protein is partly conventional, but hCG is nowhere near it. Chains of up to roughly fifty amino acids are usually called peptides; longer chains, and anything with defined tertiary structure and post-translational modification, are proteins. At 237 residues across two chains, hCG sits firmly on the protein side, and the glycosylation settles it.

Glycosylation is decisive because it is a biological process rather than a chemical one. Sugars are attached by enzymes in the endoplasmic reticulum and Golgi apparatus of a living cell, in patterns depending on the cell type. Solid-phase peptide synthesis — the method behind essentially every short research peptide in this field — assembles a bare amino acid chain one residue at a time and stops. It cannot glycosylate. A synthetic hCG chain would be the wrong molecule, because the sugars are not an accessory to the activity; they are part of it.

hCG must therefore come from a biological production system: historically purification from the urine of pregnant women, now also recombinant expression in cultured mammalian cells, which glycosylate much as a placenta would. Neither route resembles peptide manufacture, and because the carbohydrate determines half-life and receptor activity, differences in glycosylation between preparations are pharmacologically real rather than cosmetic 1. This is why the peptide-versus-protein distinction is more than taxonomy: it dictates how a molecule can be made and how it behaves once administered.

Mechanism: an LH receptor agonist

The pharmacology is simple to state. hCG is an agonist at the luteinising hormone/choriogonadotropin receptor, a G protein-coupled receptor on ovarian granulosa and theca cells and on testicular Leydig cells. Binding activates adenylate cyclase, raises intracellular cyclic AMP and drives steroidogenesis. Because hCG and LH act at the same receptor, hCG functions as a long-acting LH surrogate; its extended half-life, conferred by its glycans, is the main difference between them 1.

In the ovary, the physiological role is rescue of the corpus luteum: after conception, hCG from the developing trophoblast sustains luteal progesterone output until the placenta takes over steroid production. The same receptor action is used therapeutically to trigger ovulation, substituting for the endogenous LH surge and inducing final oocyte maturation and follicular rupture. This is routine practice in ovulation induction and assisted reproduction, and it is not in dispute.

In the testis, LH receptor agonism at Leydig cells raises intratesticular testosterone, which supports two established uses. In male hypogonadotropic hypogonadism — the testis capable, the pituitary signal missing — hCG can restore testosterone production, and with added FSH activity support spermatogenesis. Exogenous testosterone, meanwhile, suppresses pituitary LH and FSH and with them intratesticular testosterone and sperm production; hCG is used to maintain testicular function that would otherwise shut down. These are mainstream, evidence-supported indications. Any account filing hCG under fringe compounds has the picture backwards — which is what makes the rest of this article necessary.

The isoform complication

One genuine difficulty deserves stating plainly, because summaries usually flatten it out. hCG is not a single molecule but a family: regular hCG, hyperglycosylated hCG, free beta subunit, nicked forms produced by proteolysis, and the beta core fragment recovered in urine. They differ in activity as well as in name, and their classification, separate functions and clinical use were set out systematically in a review that remains the standard reference 2.

Hyperglycosylated hCG carries larger, more branched sugar chains and predominates in very early pregnancy and in trophoblastic disease. It has been described as acting principally on trophoblast growth and invasion rather than as a straightforward LH receptor agonist — a functionally distinct molecule sharing a backbone with the familiar one 1. Free beta subunit is produced by some non-trophoblastic tumours and carries different clinical meaning again.

The measurement consequence is direct. Immunoassays differ in which forms they detect: one raised against the intact dimer can under-read a sample dominated by free beta subunit, while one detecting total beta can over-read relative to biologically active hormone. A numerical hCG result is therefore not fully interpretable without knowing what the assay measures 2 — a real source of ambiguity in obstetric and oncological practice, not a laboratory technicality.

The Simeons protocol and what happened when it was tested

In the 1950s a British physician working in Rome, A. T. W. Simeons, proposed hCG as a treatment for obesity. The protocol paired injections of the hormone with a diet of approximately 500 kcal per day. The claims were specific and separable: that hCG mobilises abnormal fat stores in preference to lean tissue, redistributes fat away from characteristic deposits, suppresses the hunger such a diet would otherwise cause, and preserves wellbeing under severe restriction. Patients would therefore tolerate the diet and lose fat differently from ordinary dieters.

Those claims were testable, and they were tested. A controlled trial published in 1973 compared hCG injections against placebo injections in participants held on the restricted diet, measuring weight loss, hunger and feeling of wellbeing. The groups did not differ on any of them 3. A critical assessment of the Simeons method a few years later reviewed the accumulated literature and reached the same conclusion 4.

The definitive summary arrived in 1995. A criteria-based meta-analysis scored the published trials against a methodological checklist and pooled what remained. Its authors concluded that there is no scientific evidence hCG is effective in the treatment of obesity: it does not bring about weight loss or fat redistribution, nor reduce hunger or induce a feeling of wellbeing 5. The phrasing takes each of Simeons' four claims separately and rejects each one.

None of this means people following the protocol fail to lose weight. They lose weight, often rapidly. A diet of around 500 kcal per day supplies roughly a quarter of typical adult energy requirements, and a deficit of that size produces weight loss with or without an injection alongside. The injection is the variable the trials removed; the deficit was in both arms and never removed at all. When both groups eat the same 500 kcal and lose the same weight, the diet is doing the work 35.

The restriction itself is not benign. Intakes at that level make protein and micronutrient adequacy hard to achieve, which is why very-low-calorie regimens are conducted under medical supervision. Adverse effects reported alongside the Simeons protocol are attributable to the diet rather than the hormone 4 — the efficacy result restated from the opposite direction.

Why a refuted claim kept circulating

• Rapid, visible results. The scale moves, and the injection collects credit that belongs to the deficit.
• A genuine medicine underwriting it. hCG is prescribed in fertility and endocrine practice, so the legitimacy of the approved uses vouches for the unapproved one.
• A story with internal logic. Pregnancy mobilises maternal energy stores to support a fetus, so a pregnancy hormone that mobilises fat sounds coherent. Coherence is not evidence, and here the coherent story was tested and did not hold.
• An unfalsifiable failure mode. Weight regained afterwards is blamed on adherence rather than treatment, so the treatment never fails.
• A commercial layer. Drops, sprays and pellets marketed as containing hCG built a market with a direct interest in the claim — and an orally administered glycoprotein of this size would not reach the circulation intact anyway.

Why this case is worth keeping in mind

Two things are true about hCG at once, and holding both is the point. It is a real hormone with a defined receptor, a well-described mechanism and approved clinical uses resting on sound evidence. It is also the subject of one of the most comprehensively refuted claims in the history of obesity treatment — refuted by controlled trial 3, critical assessment 4 and criteria-based meta-analysis 5 across more than two decades, with no serious counter-evidence at any point.

The relationship between those two facts is causal, not coincidental. The diet claim was credible because the hormone was real. Nobody had to establish that hCG existed, that it was active in humans, or that it could be manufactured and administered — the fertility indications had settled all of that. What was asserted was a second, unrelated action in a different tissue, and the credibility of the first carried it. That borrowing is among the most common failure modes in how compounds in this field are described.

The pattern recurs. A compound with a documented mechanism in one tissue is described as though it acted everywhere; a molecule characterised in cell culture is discussed as though that were a clinical result. The evidence is real in each case; it is simply not evidence for the claim being made. The useful question is never whether a compound is legitimate, but whether the claim in front of you is the claim that was tested. For hCG and body weight, that question has a clean answer, which is rarer than it should be 35. The negative result does not make hCG a bad molecule. It makes it one whose real pharmacology is narrower, better defined and more interesting than the claim that made it famous.